With the launch of a new clinical trial supported by the National Institutes of Health, researchers are working to determine whether treating children diagnosed with the most severe form of fatty liver disease with a drug called cysteamine will help improve the liver.

Related posts:

  1. Vitamin E helps diminish a type of fatty liver disease in children Vitamin E helps diminish a type of fatty liver disease in children...
  2. Researchers identify cause and new treatment for common recurrent fever in children A preliminary study conducted by a team at the National Institutes of Health has identified a promising new treatment in children for the most common periodic fever disease in children. The syndrome is called periodic fever associated with aphthous stomatitis, pharyngitis and cervical adenitis — or PFAPA — and is characterized by monthly flare-ups of […]...
  3. Medicare, After 40 Years, NIH-Supported Researchers Identify Possible New Treatment for Severe Vasculitis Investigators have made a major advance in treating people with a severe form of vasculitis, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, a rare but devastating disease of blood vessels. In a six-month study, a new treatment strategy provided the same benefits as the current standard of care used for more than 40 years but required less […]...
  4. Study of youth to seek origins of heart disease among African-Americans Researchers supported by the National Institutes of Health are undertaking a preliminary study to identify the early origins of heart disease among African-Americans. The new feasibility study will enroll children and grand children of participants taking part in the largest study of heart disease risk factors among African-American adults, the Jackson Heart Study (JHS), in […]...
  5. Complications of chronic kidney disease occur earlier in children In what may lead to a shift in treatment, the largest prospective study of children with chronic kidney disease (CKD) has confirmed some experts’ suspicions that complications occur early. The findings suggest the need for earlier, more aggressive management of blood pressure, anemia and other problems associated with kidney disease, according to Dr. Marva Moxey-Mims, […]...
  6. MedicarCard.com Update – NIH Study Offers Hope to Patients with Nonalcoholic Steatohepatitis A daily dose of a specific form of vitamin E significantly improved the liver disease, nonalcoholic steatohepatitis (NASH), according to a study funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health...
  7. Medicare Mouse study shows effect of blood pressure drug on Alzheimer’s disease A drug used decades ago to treat high blood pressure has been shown to improve learning and memory in mouse models of Alzheimer’s disease, according to a new study by researchers at the National Institute on Aging (NIA), part of the National Institutes of Health. The study found that the drug, diazoxide, acted on nerve […]...
  8. Systemic lupus erythematosus: From mouse models to human disease and treatment On Sept. 2-3, 2010, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Cancer Institute (NCI), the National Institute of Allergy and Infectious Diseases (NIAID), and the NIH Office of Research on Women’s Health (ORWH) will convene a two-day conference on Systemic Lupus Erythematosus: From Mouse Models to Human Disease and […]...
  9. Study of Health Outcomes in Autistic Children and Their Families The goal of this initiative is to describe the health and health care trajectories of individuals with autism spectrum disorders (ASD) and their families, and to evaluate the feasibility of using a large population-based database for research on risk factors for ASD. The most recent prevalence data from the Centers for Disease Control and Prevention (CDC) show that one in 110 children have a diagnosis of Autism Spectrum Disorder (ASD), an increase of 57 percent between 2002 and 2006...
  10. Trace amounts of germ-killing molecules predict disease survival Investigators at the National Institutes of Health have observed that the survival rate of people with a rare immunodeficiency disease called chronic granulomatous disease (CGD) is greatly improved when even very low levels of microbe-killing molecules are present. Because production of these molecules, made by an enzyme called NADPH oxidase, can be predicted from genetic […]...
  11. HIV/AIDS Treatment Curbs Spread of HIV Among Drug Users, According to NIH Supported Study Highly active antiretroviral therapy (HAART), currently known for its therapeutic benefits against HIV, also reduced the spread of the virus among people with a history of injection drug use, according to a population-based study funded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health. The study was published […]...
  12. Medicare – Lung Disease the Links to Health People with a mild form of a common lung condition—even those without symptoms—are at increased risk for heart problems, according to a new study. This is the first report that mild, often-symptomless chronic obstructive pulmonary disease (COPD) may be linked to the heart's pumping ability...
  13. Antibody treatment protects monkeys from Hendra virus disease A human antibody given to monkeys infected with the deadly Hendra virus completely protected them from disease, according to a study published by National Institutes of Health (NIH) scientists and their collaborators....
  14. NIH-Funded Study Finds Early HAART during TB Treatment Boosts Survival Rate in People Co-Infected with HIV and TB A clinical trial in Cambodia has found it possible to prolong the survival of untreated HIV-infected adults with very weak immune systems and newly diagnosed tuberculosis (TB) by starting anti-HIV therapy two weeks after beginning TB treatment, rather than waiting eight weeks, as has been standard. This finding by scientists co-funded by the National Institute […]...
  15. Medicare Card, Stroke Prevention Study, Children with Sickle Cell Anemia, Iron Overload Stopped Early The National Heart, Lung, and Blood Institute (NHLBI) has stopped a clinical trial evaluating a new approach to reduce the risk of recurrent stroke in children with sickle cell anemia and iron overload because of evidence that the new treatment was unlikely to prove better than the existing treatment....